Far-Western based protein-protein interaction screening of high-density protein filter arraysMAHLKNECHT, Ulrich; OTTMANN, Oliver G; HOELZER, Dieter et al.Journal of biotechnology. 2001, Vol 88, Num 2, pp 89-94, issn 0168-1656Article

Targeted therapies in the treatment of philadelphia chromosome-positive acute lymphoblastic leukemiaHOELZER, Dieter; GOKBUGET, Nicola; OTTMANN, Oliver G et al.Seminars in hematology. 2002, Vol 39, Num 4, pp 32-37, issn 0037-1963, 6 p., SUP3Article

Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemiaOTTMANN, Oliver G; BUG, Gesine; KRAUTER, Jürgen et al.Seminars in hematology. 2007, Vol 44, Num 3, pp 183-192, issn 0037-1963, 10 p.Article

Imatinib in the treatment of philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving conceptsOTTMANN, Oliver G; WASSMANN, Barbara.Baillière's best practice & research. Clinical haematology. 2002, Vol 15, Num 4, pp 757-769, issn 1521-6926, 13 p.Article

p185^BCR/ABL has a lower sensitivity than p210^BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemiaMIAN, Afsar A; METODIEVA, Anna; NAJAJREH, Yousef et al.Haematologica (Roma). 2012, Vol 97, Num 2, pp 251-257, issn 0390-6078, 7 p.Article

Coordination of cell growth in cocultures by a genetic proliferation control systemSCHROEDER, Katharina; KOSCHMIEDER, Steffen; OTTMANN, Oliver G et al.Biotechnology and bioengineering. 2002, Vol 78, Num 3, pp 346-352, issn 0006-3592Article

FLT3-ITD-, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatmentDALI CAI; YING WANG; OTTMANN, Oliver G et al.Blood. 2006, Vol 107, Num 5, pp 2094-2097, issn 0006-4971, 4 p.Article

Short Communication: Inhibition of X4-Tropic HIV Type 1 Replication by Knockdown of the Cellular Protein LEREPO4CAPALBO, Gianni; MÜLLER-KULLER, Thea; DIETRICH, Ursula et al.AIDS research and human retroviruses. 2010, Vol 26, Num 10, pp 1155-1161, issn 0889-2229, 7 p.Article

Targeting the oligomerization domain of ETO interferes with RUNX1/ ETO oncogenic activity in t(8;21)-positive leukemic cellsWICHMANN, Christian; LINPING CHEN; HEINRICH, Markus et al.Cancer research (Baltimore). 2007, Vol 67, Num 5, pp 2280-2289, issn 0008-5472, 10 p.Article

Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALLKANTARJIAN, Hagop; GILES, Francis; BOCHINSKI, Kathy et al.The New England journal of medicine. 2006, Vol 354, Num 24, pp 2542-2551, issn 0028-4793, 10 p.Article

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylatePFEIFER, Heike; WASSMANN, Barbara; LÜBBERT, Michael et al.Clinical cancer research. 2003, Vol 9, Num 13, pp 4674-4681, issn 1078-0432, 8 p.Article

An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCRMÜLLER, Martin C; SAGLIO, Giuseppe; STOCKINGER, Hubertus et al.Haematologica (Roma). 2007, Vol 92, Num 7, pp 970-973, issn 0390-6078, 4 p.Article

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ALL)WASSMANN, Barbara; PFEIFER, Heike; GANSER, Arnold et al.Blood. 2006, Vol 108, Num 5, pp 1469-1477, issn 0006-4971, 9 p.Article

Zoledronate synergises with imatinib mesylate to inhibit Ph⁺ primary leukaemic cell growthSEGAWA, Hidekazu; KIMURA, Shinya; OTTMANN, Oliver G et al.British journal of haematology. 2005, Vol 130, Num 4, pp 558-560, issn 0007-1048, 3 p.Article

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemiaBUG, Gesine; BITTER, Markus; NEUBAUER, Andreas et al.Cancer. 2005, Vol 104, Num 12, pp 2717-2725, issn 0008-543X, 9 p.Article

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)SCHEURING, Urban J; PFEIFER, Heike; WASSMANN, Barbara et al.Blood. 2003, Vol 101, Num 1, pp 85-90, issn 0006-4971, 6 p.Article

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaFIEDLER, Walter; MESTERS, Rolf; KUSE, Rolf et al.Blood. 2003, Vol 102, Num 8, pp 2763-2767, issn 0006-4971, 5 p.Article

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph⁺ leukemia activity of imatinib mesylateKURODA, Junya; KIMURA, Shinya; MAEKAWA, Taira et al.Blood. 2003, Vol 102, Num 6, pp 2229-2235, issn 0006-4971, 7 p.Article

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsTANAKA, Ruriko; SQUIRES, Matthew S; LYONS, John F et al.Blood. 2010, Vol 116, Num 12, pp 2089-2095, issn 0006-4971, 7 p.Article

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisisFRUEHAUF, Stefan; TOPALY, Julian; HO, Anthony D et al.Cancer. 2007, Vol 109, Num 8, pp 1543-1549, issn 0008-543X, 7 p.Article

Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ ALL). CommentaryHUGHES, Timothy; BRANFORD, Susan; WYSTUB, Silvia et al.Blood. 2007, Vol 110, Num 2, issn 0006-4971, 472, 727-734 [9 p.]Article

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ALL) treated with imatinibWASSMANN, Barbara; PFEIFER, Heike; SCHWERDTFEGER, Rainer et al.Blood. 2004, Vol 103, Num 4, pp 1495-1498, issn 0006-4971, 4 p.Article

p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acidKURODA, Junya; KIMURA, Shinya; MAEKAWA, Taira et al.Cancer science. 2004, Vol 95, Num 2, pp 186-192, issn 1347-9032, 7 p.Article

Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosisPUCCETTI, Elena; BEISSERT, Tim; GÜLLER, Saskia et al.Oncogene (Basingstoke). 2003, Vol 22, Num 44, pp 6900-6908, issn 0950-9232, 9 p.Article

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLTOPP, Max S; GÖKBUGET, Nicola; STELLJES, Matthias et al.Blood. 2012, Vol 120, Num 26, pp 5185-5187, issn 0006-4971, 3 p.Article